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text of the methods section, I may have missed it although I understand this indirectly, else it could possibly be extended to some extent to make it easier for the reader at an early stage to understand this.
Comment 4: I think it was not described when the first patient is anticipated to be included. This is generally described in a design paper.
Comment 5: I think the text regarding induvidualised endpoints was a bit difficult to understand. Could this be extended to some extent? And regarding having a goal of 64 mmol/mol in patients who have had a severe hypoglycaemia I think is a bit strange target as a generalised target. Of T1D patients I think about 50% have a severe hypo at any time and we have similar targets. I think it depends a lot depending how long time it was since the severe hypo appeared, during what circumstances and if it is judged that it can likely be avoided in the future by changed therapy or education. E.g. if a patient happened to take meal-time instead of basal insulin or getting a hypo at very high level of exercise without reducing insulin doses a similar situation could likely be avoided and a high HbA1c goal may not be needed. However, in the end this is up to the authors. The most essential part is that it is the same in both arms which I interpret it is.
Comment 6. Methods -statistics -I see that for the primary endpoint it is said that the absolute difference in HbA1c at the final study visit will be compared between groups. To my experience in randomized studies it is more common that the change from baseline to final visit is compared between groups. However, I think in the end these two approaches will give the "same results" but the authors could check with their statistician that they prefer to have the absolute difference between groups. Although this can likely be changed in a SAP, it is good if stating in a design article for the primary endpoint if the same analysis in the end can be used and similarly the primary endpoint is generally stated in an official database.
Comment 7: For analyses of endpoints it is generally given if the primary analysis will be an Intention to Treat Analysis or another type of analysis, i.e. on what population the analysis will be performed. Please add this information.
Comment 8: Under the heading monitoring it says if I understand it correctly that monitoring is not needed since usual clinical care is part of the study besides the intervention. To my knowledge this is not any reason for not having monitoring. Still this is a clinical trial since an intervention not performed in clinical practice will be performed. Than according to GCP monitoring is recommended. It would also improve the validity of the study to include monitoring. Monitoring is both essential as a support for guiding participating sites to follow protocol but also as a type of control function supporting that the trial was really done in accordance with the protocol -"checked" by an independent party and for patients safety. It may be difficult to have resources for monitoring all data which is often performed in trials sponsored by companies. A solution can then be that the primary endpoint and adverse events is monitored in all participants whereas random checks are performed for less important endpoints.
Comment 9: I agree that in a CGM trial it is not necessary to register all non-severe adverse events. In T1D trials it is e.g relatively common to only register severe hypos and diabetes ketoacidoses. However, Serious Adverse Events are also generally registered. For patients safety I think it is necessary that serious adverse events are registered in addition to severe hypos. I would also recommend that local skin reactions from the libre-pro is registered since this is a common problem in the form of skin reactions in persons with T1D in clinical practice.
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GENERAL COMMENTS
A well-planned protocol. The outcome of the trial would be able to provide more insights into the utility of this novel retrospective CGM.
One suggestion would be subjects could be categorized as subgroups based on age and presence of co-morbidities, instead of setting the bar at a wide range from 18-80 years of age and including all subjects under this group, especially while considering their HbA1c targets; HbA1c could be individualized for every subgroup and then r-CGM compared between the intervention and the control for every subgroup.
As a suggesion, at a quick glance, the fourth point given in the abstract session 'Strengths and limitations of this study', would require a little more clarification -"Despite individual randomisation, potential contamination between study arms will be minimised as the amount of glucose data available to GPs in managing intervention and control group participants will differ significantly."
Few more relevant references may be included. Comment 2: In the background the authors note that there are only a couple of small randomized studies of CGM in T2D. There are two relatively large trials in T2D treated with MDI; one with the Libre system and one with DexCom. This is a special group but I think these two studies however should be cited either in the background or discussion.
While these trials are of real-time CGM, we have added reference to these trials on page 6:
"Two trials of real-time CGM (i.e. unblinded) have been conducted in a select population of adults with T2D treated using multiple daily injections of insulin (MDI): neither resulted in a clinically significant improvement in HbA1c
, and while one reduced hypoglycaemia and improved treatment satisfaction, the other did not [25, 26] Comment 3. I understand that the controls also will wear the LibrePro to be able to compare variables like time in range, time in hypo etc. but that the care-givers will not be allowed to look at data nor the patients. Please check that this is clearly described in the text of the methods section, I may have missed it although I understand this indirectly, else it could possibly be extended to some extent to make it easier for the reader at an early stage to understand this.
The following text is already present in the methods section, page 11:
"Participants in the intervention arm will be able to see their baseline r-CGM tracing as part of their baseline clinic assessment visit, while those randomised to the control arm will not have access to their baseline r-CGM tracing. The final 12-month tracing will be available to participants in both arms (following final data collection), enabling the GP and PN to use that as part of clinical management for all study participants."
However, we have edited the following text earlier in the methods section (page 10) to clarify this point earlier, as suggested:
"Those randomised to the control group will wear the r-CGM device at baseline but the data will be blinded to both the patient participant and their GP. They will continue to receive usual clinical care." Comment 4: I think it was not described when the first patient is anticipated to be included. This is generally described in a design paper.
The following text has been added on page 8 "Participant recruitment commenced in October 2016 and was completed in October 2017. Final follow up is anticipated to be completed in October 2018." Comment 5: I think the text regarding individualised endpoints was a bit difficult to understand. Could this be extended to some extent? And regarding having a goal of 64 mmol/mol in patients who have had a severe hypoglycaemia I think is a bit strange target as a generalised target. Of T1D patients I think about We thank the reviewer for the comment. We agree that it is important to make appropriate therapeutic changes to avoid hypoglycaemia. However, our primary outcome is HbA1c, and hence it is important for us to understand what HbA1c goal the GP and patient are aiming for. 50% have a severe hypo at any time and we have similar targets. I think it depends a lot depending how long time it was since the severe hypo appeared, during what circumstances and if it is judged that it can likely be avoided in the future by changed therapy or education. E.g. if a patient happened to take meal-time instead of basal insulin or getting a hypo at very high level of exercise without reducing insulin doses a similar situation could likely be avoided and a high HbA1c goal may not be needed. However, in the end this is up to the authors. The most essential part is that it is the same in both arms which I interpret it is.
Australian Guidelines have set a target of 64 mmol/mol in the management of T2DM for people with two or more previous episodes of severe hypoglycaemia GPs can set an individualised target for all participants in both the intervention and control groups prior to randomisation. We envisage that this will be infrequent and will be balanced, at random, between the intervention and control groups.
Yes, we can confirm that the primary endpoint is the absolute difference between groups in HbA1c at 12 months. This has been checked with the study statistician and is consistent with the trial registry.
We are using a mixed model for this analysis. The outcome vector will include HbA1c at baseline, 6 months and 12 months. This will give us the same results as modelling the change in HbA1c or modelling the HbA1c at 12 months and adjusting for baseline, as indicated by the reviewer.
On page 13 it already states "Analysis will be based on an intention to treat approach." Comment 8: Under the heading monitoring it says if I understand it correctly that monitoring is not
We thank the reviewer for the comment. In fact, we are collecting data on the fidelity of the needed since usual clinical care is part of the study besides the intervention. To my knowledge this is not any reason for not having monitoring. Still this is a clinical trial since an intervention not performed in clinical practice will be performed. Than according to GCP monitoring is recommended. It would also improve the validity of the study to include monitoring. Monitoring is both essential as a support for guiding participating sites to follow protocol but also as a type of control function supporting that the trial was really done in accordance with the protocol -"checked" by an independent party and for patients safety. It may be difficult to have resources for monitoring all data which is often performed in trials sponsored by companies. A solution can then be that the primary endpoint and adverse events is monitored in all participants whereas random checks are performed for less important endpoints.
intervention. We are monitoring if GPs have undertaken the training in r-CGM use and interpretation. We monitor adherence to the 3 monthly visits through collection of Clinic Assessment Visit (CAV) forms. In the Clinic Assessment visits in the intervention group the form asks if any technical problems have been encountered in relation to the sensor. This includes local skin reactions. We have added the following text on page 13:
"We will collect data on the fidelity of the intervention (if GPs have undertaken the training in r-CGM use and interpretation and adherence to the 3-monthly visits through collection of Clinic Assessment Visit (CAV) forms which also ask if any technical problems have been encountered in relation to the sensor, including local skin reactions)."
As noted already on page 13: ." A safety monitoring committee consisting of one GP, one RN-CDE and one endocrinologist will be appointed to review significant adverse events, which includes any episodes of severe hypoglycaemia, and their duration, treatment and outcome. "
See also our comment above on skin reactions Reviewer 2 One suggestion would be subjects could be categorized as subgroups based on age and presence of co-morbidities, instead of setting the bar at a wide range from 18-80 years of age and including all subjects under this group, especially while considering their HbA1c targets; HbA1c could be individualized for every subgroup and then r-CGM compared between the intervention and the control for every subgroup.
While the reviewer makes an interesting suggestion, our study is not powered to undertake these sub-group analyses. Our only pre-specified sub-group analyses are referred to on page 13: "A secondary analysis will examine whether the intervention effect differs between those with and without a history of severe hypoglycaemia. The same approach will be used to determine whether the intervention effect varies for those with a general HbA1c target compared to those with a personalised HbA1c target."
As a suggestion, at a quick glance, the fourth point given in the abstract session 'Strengths and limitations of this study', would require a little more clarification -"Despite individual randomisation, potential contamination between study arms will be minimised as the amount of glucose data available to GPs in managing intervention and control group participants will differ significantly."
On page 14, we have expanded on this point, as suggested: We have not included the reference to Allen et al (2008) because the aim of that study was to use CGM to increase self-efficacy for and levels of physical activity. As our primary aim is to determine the effect on HbA1c, we do not consider this paper to be sufficiently relevant. Also, the technology has advanced considerably in the past decade, so this paper is somewhat less relevant than those by Beck, Haak and Kesavadev. Comment 1. Regarding monitoring of the study which is recommended by GCP I do not agree with the text below in the manuscript regarding monitoring.
"Monitoring
As this pragmatic trial is embedded in routine clinical care, a data monitoring committee is not considered necessary. We will collect data on the fidelity of the intervention (if GPs have undertaken the training in r-CGM use and interpretation and adherence to the 3-monthly visits through collection of Clinic Assessment Visit (CAV) forms, which also ask if any technical problems have been encountered in relation to the sensor, including local skin reactions). A safety monitoring committee consisting of one GP, one RN-CDE and one endocrinologist will be appointed to review significant adverse events, which includes any episodes of severe hypoglycaemia, and their duration, treatment and outcome."
It is noteworthy that monitoring is a very essential part of randomized trials. It has two main purposes namely to control that one can rely on results so that the protocol is followed by all sites and that data are correct and secondly to support the research team that sites follow the protocol. Most essential is always that informed consent is monitored and secondly that the primary endpoint, in this case HbA1c as well as serious adverse events are monitored by an independent monitor. As I understand this is not the case it is a major limitation of the study, especially since this is recommended by GCP. I would recommend, although this is not optimally, that one consults an independent monitor to perform a monitoring for the rest of the study and at finalisation. In my view this has nothing to do whether patients continue with some parts in clinical care. This is often the case in trials that some procedures in clinical care or many are continued in addition to the trial. But here is a clear novel therapy = intervention = rCGM for patients not used in general clinical practice hence defined as a clinical trial and thereby being need of following GCP for as well safety reasons, credibility of results etc. Hence, the following sentence should be deleted:
"As this pragmatic trial is embedded in routine clinical care, a data monitoring committee is not considered necessary."
In the discussion under the section limitation it should be noticed that "A limitation of this study is that no independent monitoring was performed".
Comment 2: As I understand the only adverse events collected are skin reactions and severe hypoglycaemia. How were these assessed. In clinical trials a procedure should exist to document these structurally e.g. at each clinical visits by examinations and asking patients. Need to be added in the method how these were collected.
Comment 3: As I understand serious adverse events were not structurally collected or not even planned to be collected in any way. This is generally a minimum for adverse events from a safety perspective. It needs to be added in the limitation section that serious adverse events were not structurally assessed.
Comment 4: In the methods section I think it should be more clearly described how the primary endpoint absolute difference in HbA1c shall be estimated. Especially since this publication will be so close to finalisation of the trial. This will ensure for readers that it was predefined. Which statistical method will be used, B) What will be used for missing HbA1c-values, imputations, LOCF or what C) Will adjustment for baseline HbA1c be performed, if not please mention this.
VERSION 2 -AUTHOR RESPONSE Comment Response
Comment: I think the authors have responded well on several questions. I have however a few follow-up comments.
We thank the reviewer Comment 1. Regarding monitoring of the study which is recommended by GCP I do not agree with the text below in the manuscript regarding monitoring.
"Monitoring
As this pragmatic trial is embedded in routine clinical care, a data monitoring committee is not considered necessary. We will collect data on the fidelity of the intervention (if GPs have undertaken the training in r-CGM use and interpretation and adherence to the 3-monthly visits through collection of Clinic Assessment Visit (CAV) forms, which also ask if any technical
We have addressed the reviewer's concerns on pages 13 and 15
problems have been encountered in relation to the sensor, including local skin reactions). A safety monitoring committee consisting of one GP, one RN-CDE and one endocrinologist will be appointed to review significant adverse events, which includes any episodes of severe hypoglycaemia, and their duration, treatment and outcome."
It is noteworthy that monitoring is a very essential part of randomized trials. It has two main purposes namely to control that one can rely on results so that the protocol is followed by all sites and that data are correct and secondly to support the research team that sites follow the protocol. Most essential is always that informed consent is monitored and secondly that the primary endpoint, in this case HbA1c as well as serious adverse events are monitored by an independent monitor. As I understand this is not the case it is a major limitation of the study, especially since this is recommended by GCP. I would recommend, although this is not optimally, that one consults an independent monitor to perform a monitoring for the rest of the study and at finalisation. In my view this has nothing to do whether patients continue with some parts in clinical care. This is often the case in trials that some procedures in clinical care or many are continued in addition to the trial. But here is a clear novel therapy = intervention = rCGM for patients not used in general clinical practice hence defined as a clinical trial and thereby being need of following GCP for as well safety reasons, credibility of results etc.
Hence, the following sentence should be deleted:
Comment added page 13 "Adverse events may also be reported at Clinic Assessment Visits and are collected at follow up data collection using standard operating procedures."
We have now addressed this on page 15
"Limitations of our study are that no independent monitoring has been performed and that serious adverse events were not structurally assessed (ie reporting was dependent on the clinicians at the participating practices).
We have addressed how the primary endpoint will be estimated with the statement:
"A linear mixed effects model (i.e. with both fixed effect for treatment and time and random effect for clinic and repeated patient HbA1c measurements) will be used to estimate the group difference in HbA1c at 12 months using restricted maximum likelihood estimation."
We have edited the section on page 13 "Analysis will be based on an intention to treat approach. Mixed models assume any missing data are missing at random. Hence, sensitivity analyses will be conducted to assess the robustness of this assumption. A full statistical analysis plan for the trial will be published separately"
In using a mixed model, we have stated (page 13):
"The model will include the HbA1c at baseline, 6 months and 12 months and be adjusted by age and history of hypoglycaemia should these be imbalanced between the arms at baseline." This is equivalent to adjusting for baseline in the model.
